Search Result

Results for "

Peptide vaccine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (2) Apoptosis (2) Biochemical Assay Reagents (6) CD74 (1) Drug Intermediate (3) EGFR (2) HIV (3) HPV (1) IFNAR (1) Influenza Virus (2) Ligands for E3 Ligase (1) MDM-2/p53 (1) MHC (8) Necroptosis (2) NF-κB (4) Nuclear Factor of activated T Cells (NFAT) (1) Ras (2) Reference Standards (1) SARS-CoV (1) Tau Protein (1) Telomerase (1) Toll-like Receptor (TLR) (3) Tyrosinase (1)
By Research Areas:	Cancer (25) Infection (10) Inflammation/Immunology (23) Neurological Disease (4)
Oligonucleotides:	Adjuvant (1)

Inhibitors & Agonists

Bibliotecas de Screening

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Oligonucleotides

Targets Recommended: RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-P1439

RS 09 Maximum Cited Publications 18 Publications Verification	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
RS 09 is an LPS (HY-D1056) peptide mimic and TLR4 agonist. RS 09 can bind to TLR-4 and activate NF-κB. RS 09 can function as an adjuvant in vivo, enhancing the antigen-specific immune response .

HY-104004

Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH; Fmoc-Ser[GalNAc(Ac)3-α-D]-OH; Fmoc-Ser(Ac3AcNH-α-Gal)-OH	Amino Acid Derivatives Drug Intermediate	Cancer
Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis .

HY-P11303

PADRE peptide	CD74 MHC	Neurological Disease Cancer
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 ⁺ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 ⁺ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .

HY-165613

Pam2Cys Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine	Toll-like Receptor (TLR) Influenza Virus NF-κB	Infection Inflammation/Immunology
Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection .

HY-P1684

Peptide P60 1 Publications Verification FOXP3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 ⁺CD25 ⁺Foxp3 ⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .

HY-P11058

OVA(250-264) OVAp	MHC	Cancer
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 ⁺ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .

HY-P11294

KLVVVGADGVGKSALTI	Ras	Cancer
KLVVVGADGVGKSALTI is a KRAS G12D targeting peptide that can be used in tumor research .

HY-P1439A

RS 09 TFA Maximum Cited Publications 18 Publications Verification	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
RS 09 TFA is an LPS (HY-D1056) peptide mimic and TLR4 agonist. RS 09 TFA can bind to TLR-4 and activate NF-κB. RS 09 TFA can function as an adjuvant in vivo, enhancing the antigen-specific immune response .

HY-P1771A

OVA G4 peptide TFA	Biochemical Assay Reagents	Inflammation/Immunology
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P11060

MC38 SLP Adpgk Adpgk Peptide	MHC	Cancer
MC38 SLP Adpgk (Adpgk peptide) is an H-2 K ^b-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice .

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-105067A

Tertomotide hydrochloride GV-1001 hydrochloride	Telomerase	Neurological Disease
Tertomotide (GV1001) hydrochloride is peptide vaccine consists a 16-aa human telomerase reverse transcriptase (hTERT) sequence. Tertomotide hydrochloride shows neuroprotective. Tertomotide hydrochloride has the potential for the research of Alzheimer's disease .

HY-106204

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets HER2. Nelipepimut-S has immune activity against HER2 positive breast cancer .

HY-P10701

Q11 peptide	Biochemical Assay Reagents	Inflammation/Immunology Cancer
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .

HY-P3129

KRAS G13D peptide, 25 mer	Ras	Inflammation/Immunology Cancer
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .

HY-P10686

CH401 peptide	EGFR	Cancer
CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate .

HY-P1771

OVA G4 peptide	Biochemical Assay Reagents	Inflammation/Immunology
OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P4055

GP120, HIV-1 MN	HIV	Infection Inflammation/Immunology
GP120, HIV-1 MN is a peptide. GP120, HIV-1 MN can be used for the research of HIV infection .

HY-P2520

Influenza HA (110-119)	Influenza Virus	Inflammation/Immunology
Influenza HA (110-119) is the 110-119 fragment of influenza virus hemagglutinin that can stimulate Treg cells proliferation .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine* .

HY-P11090

TpD	MHC	Inflammation/Immunology
TpD is a chimeric T-helper epitope. TpD has a special site that cathepsin can cut. Immunization with TpD produces a strong antibody response. TpD promotes long-term CD4 immune responses in animals and humans. TpD binds well to many human MHC class II types, mainly HLA-DRB1. It also binds some other HLA alleles like DRB3, DRB4, DRB5, DP, and DQ. TpD can be used to improve the immune response of peptide vaccines .

HY-P5334A

AADvac 1 TFA	Tau Protein	Neurological Disease
AADvac 1 TFA is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 TFA is composed of a regulatory peptide ²⁹⁴KDNIKHVPGGGS ³⁰⁵ that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .

HY-P10251

HIV gp120 (318-327)	HIV	Infection
HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .

HY-NP0211

DHT-OVA	Biochemical Assay Reagents	Inflammation/Immunology
DHT-OVA is a conjugate of DHT (Dihydrotestosterone) and OVA peptide. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-156087G

Cholicamideβ (GMP)	Apoptosis Necroptosis	Cancer
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

HY-156087

Cholicamideβ	Apoptosis Necroptosis	Cancer
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

HY-P10976

Spike Glycoprotein (1147-1162)	SARS-CoV	Infection
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .

HY-P3070

H2-D b restricted epitopes VSV Nucleoprotein (52-59)	MHC	Infection Others
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .

HY-P11407

HIV-1 GAG peptide A-I	HIV	Infection
HIV-1 GAG peptide A-I is a specific HIV-1 Gag peptide sequence, known to be a CD8 ⁺ T cell epitope. HIV-1 GAG peptide A-I can be used for the research of HIV vaccines. .

HY-183207

CD56 peptide/BSA	Biochemical Assay Reagents	Others
CD56 peptide/BSA is an antigen-adjuvant conjugate conjugate of CD56 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.

HY-183208

Ki-67 peptide/BSA	Biochemical Assay Reagents	Others
Ki-67 peptide/BSA is an antigen-adjuvant conjugate conjugate of Ki-67 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.

HY-P11123

MSP-1 (20-39)	IFNAR	Infection Inflammation/Immunology
MSP-1 (20-39) is a peptide segment that can induce the production of IFN-γ. MSP-1 (20-39) has the potential to serve as a malaria vaccine. MSP-1 (20-39) can be used for research on malaria or immunology .

HY-P11397

VLPDVFIRCV	MHC	Cancer
VLPDVFIRCV, a melanoma antigen-derived peptide, is the intron sequence (nt 38-67) of the N-acetylglucosamine transferase V (GnT-V) gene. VLPDVFIRCV has a high affinity for MHC-I class molecules, but it cannot activate the immune response against natural tumor cells. The cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in the chromium release experiment. VLPDVFIRCV can be used for vaccine design research .

HY-P11084A

WT1 126-134 peptide acetate	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .

HY-183596

L-His-BPA	Drug Intermediate	Cancer
L-His-BPA is a prodrug of L-p-Boronophenylalanine (L-BPA) (HY-W087830), formed by the peptide bond linkage of L-histidine (L-His) (HY-N0832) and L-BPA. L-His-BPA is rapidly cleaved by endogenous proteases to de novo release L-BPA in the systemic circulation. When used in combination with neutron irradiation, L-His-BPA induces complete and durable tumor regression, elicits cancer vaccine responses, and produces abscopal inhibitory effects on unirradiated distant tumors. L-His-BPA can be used in studies of boron neutron capture therapy (BNCT) for relapsed/advanced solid tumors .

HY-104004R

Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard) Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH (Standard); Fmoc-Ser[GalNAc(Ac)3-α-D]-OH (Standard); Fmoc-Ser(Ac3AcNH-α-Gal)-OH (Standard)	Amino Acid Derivatives Reference Standards Drug Intermediate	Cancer
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard) is the analytical standard of Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (HY-104004). This product is intended for research and analytical applications. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis .

Cat. No.	Nombre del producto

HY-L105

Peptide Library	2,520 compounds
Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. MedChemExpress (MCE) offers a comprehensive collection of 2,520 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Peptide Library

2,520 compounds

Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.

MedChemExpress (MCE) offers a comprehensive collection of 2,520 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

HY-L110

Cyclic Peptide Library	97 compounds
Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs. MCE offers a unique collection of 97 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cyclic Peptide Library

97 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 97 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Nombre del producto	Type

HY-156087G

Cholicamideβ (GMP)	Fluorescent Dyes
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

Cat. No.	Nombre del producto	Type

HY-163551

BNP peptide/KLH	Biochemical Assay Reagents
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

BNP peptide/KLH

Biochemical Assay Reagents

The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-NP0211

DHT-OVA	Biochemical Assay Reagents
DHT-OVA is a conjugate of DHT (Dihydrotestosterone) and OVA peptide. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-156087G

Cholicamideβ (GMP)	Biochemical Assay Reagents
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

HY-183207

CD56 peptide/BSA	Biochemical Assay Reagents
CD56 peptide/BSA is an antigen-adjuvant conjugate conjugate of CD56 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.

HY-183208

Ki-67 peptide/BSA	Biochemical Assay Reagents
Ki-67 peptide/BSA is an antigen-adjuvant conjugate conjugate of Ki-67 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.

Cat. No.	Nombre del producto	Target	Research Area

HY-P1439

RS 09 Maximum Cited Publications 18 Publications Verification	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
RS 09 is an LPS (HY-D1056) peptide mimic and TLR4 agonist. RS 09 can bind to TLR-4 and activate NF-κB. RS 09 can function as an adjuvant in vivo, enhancing the antigen-specific immune response .

HY-P11303

PADRE peptide	CD74 MHC	Neurological Disease Cancer
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 ⁺ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 ⁺ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .

HY-P1684

Peptide P60 1 Publications Verification FOXP3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 ⁺CD25 ⁺Foxp3 ⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .

HY-P11058

OVA(250-264) OVAp	MHC	Cancer
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 ⁺ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .

HY-P4909

Autoinducing Peptide I AIP-I	Peptides	Infection
Autoinducing Peptide I is a cyclic octapeptide secreted by Staphylococcus aureus and can be used in vaccine research .

HY-P11294

KLVVVGADGVGKSALTI	Ras	Cancer
KLVVVGADGVGKSALTI is a KRAS G12D targeting peptide that can be used in tumor research .

HY-P1439A

RS 09 TFA Maximum Cited Publications 18 Publications Verification	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
RS 09 TFA is an LPS (HY-D1056) peptide mimic and TLR4 agonist. RS 09 TFA can bind to TLR-4 and activate NF-κB. RS 09 TFA can function as an adjuvant in vivo, enhancing the antigen-specific immune response .

HY-P1771A

OVA G4 peptide TFA	Biochemical Assay Reagents	Inflammation/Immunology
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P11060

MC38 SLP Adpgk Adpgk Peptide	MHC	Cancer
MC38 SLP Adpgk (Adpgk peptide) is an H-2 K ^b-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice .

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-106204

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets HER2. Nelipepimut-S has immune activity against HER2 positive breast cancer .

HY-P10701

Q11 peptide	Biochemical Assay Reagents	Inflammation/Immunology Cancer
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .

HY-P5334

AADvac 1	Peptides	Neurological Disease
AADvac 1 is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 is composed of a regulatory peptide ²⁹⁴KDNIKHVPGGGS ³⁰⁵ that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .

HY-P3129

KRAS G13D peptide, 25 mer	Ras	Inflammation/Immunology Cancer
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .

HY-P10686

CH401 peptide	EGFR	Cancer
CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate .

HY-P1771

OVA G4 peptide	Biochemical Assay Reagents	Inflammation/Immunology
OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P11059

MC38 SLP Reps1 Reps1 Peptide	Peptides	Cancer
MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines .

HY-P4055

GP120, HIV-1 MN	HIV	Infection Inflammation/Immunology
GP120, HIV-1 MN is a peptide. GP120, HIV-1 MN can be used for the research of HIV infection .

HY-P2520

Influenza HA (110-119)	Influenza Virus	Inflammation/Immunology
Influenza HA (110-119) is the 110-119 fragment of influenza virus hemagglutinin that can stimulate Treg cells proliferation .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine* .

HY-P11090

TpD	MHC	Inflammation/Immunology
TpD is a chimeric T-helper epitope. TpD has a special site that cathepsin can cut. Immunization with TpD produces a strong antibody response. TpD promotes long-term CD4 immune responses in animals and humans. TpD binds well to many human MHC class II types, mainly HLA-DRB1. It also binds some other HLA alleles like DRB3, DRB4, DRB5, DP, and DQ. TpD can be used to improve the immune response of peptide vaccines .

HY-P5078

NPNA hexamer	Peptides	Infection
NPNA hexamer is a peptide. NPNA hexamer can be used for the research of malaria and the development of a sporozoite vaccine .

HY-P3315

Onilcamotide RV001	Peptides	Inflammation/Immunology Cancer
Onilcamotide (RV001) is a C-terminal peptide of RhoC protein. Onilcamotide is a cancer vaccine and has potential immunomodulating and antineoplastic activities .

HY-P5334A

AADvac 1 TFA	Tau Protein	Neurological Disease
AADvac 1 TFA is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 TFA is composed of a regulatory peptide ²⁹⁴KDNIKHVPGGGS ³⁰⁵ that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .

HY-P5744

SPPHPSPAFSPAFDNLYYWDQ	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743

IRGRILHDGAYSLTLQGLGIH	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743A

IRGRILHDGAYSLTLQGLGIH TFA	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH TFA is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P10251

HIV gp120 (318-327)	HIV	Infection
HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-P10507

MART-1 nonamer antigen	Peptides	Cancer
MART-1 nonamer antigen (LAGIGILTV) is a melanoma antigen that can be recognized by T cells. MART-1 nonamer antigen behaves as a superagonist by in vitro inducing specific T cells with enhanced immunological functions. MART-1 nonamer antigen can be used as a model to design peptides for use in anti-tumour vaccines .

HY-P10021

Tapderimotide hTERT (691–705)	Peptides	Inflammation/Immunology
Tapderimotide (hTERT (691–705)) is an immunological agent for active immunization .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

HY-P10976

Spike Glycoprotein (1147-1162)	SARS-CoV	Infection
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .

HY-P3070

H2-D b restricted epitopes VSV Nucleoprotein (52-59)	MHC	Infection Others
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .

HY-P11407

HIV-1 GAG peptide A-I	HIV	Infection
HIV-1 GAG peptide A-I is a specific HIV-1 Gag peptide sequence, known to be a CD8 ⁺ T cell epitope. HIV-1 GAG peptide A-I can be used for the research of HIV vaccines. .

HY-P11435

KQSSKALQR	Peptides	Cancer
KQSSKALQR is a BCR-ABL peptide. KQSSKALQR can induce CD8 ⁺T cell responses. KQSSKALQR can be used in vaccine research for chronic myeloid leukaemia (CML) .

HY-P5744A

SPPHPSPAFSPAFDNLYYWDQ TFA	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P11123

MSP-1 (20-39)	IFNAR	Infection Inflammation/Immunology
MSP-1 (20-39) is a peptide segment that can induce the production of IFN-γ. MSP-1 (20-39) has the potential to serve as a malaria vaccine. MSP-1 (20-39) can be used for research on malaria or immunology .

HY-P11397

VLPDVFIRCV	MHC	Cancer
VLPDVFIRCV, a melanoma antigen-derived peptide, is the intron sequence (nt 38-67) of the N-acetylglucosamine transferase V (GnT-V) gene. VLPDVFIRCV has a high affinity for MHC-I class molecules, but it cannot activate the immune response against natural tumor cells. The cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in the chromium release experiment. VLPDVFIRCV can be used for vaccine design research .

HY-P11084A

WT1 126-134 peptide acetate	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .

Cat. No.	Nombre del producto		Classification

HY-156087

Cholicamideβ		Adjuvant
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: